BibTex RIS Cite

Current Treatment of Medulloblastoma

Year 2013, Volume: 46 Issue: 1, 32 - 38, 01.04.2013

Özlem Derinalp Or Yıldız Yükselen Güney Ayşen Dizman Gonca Altınışık İnan Gülhan Güler Avcı Muzaffer Bedri Altundag

https://doi.org/10.5505/aot.2013.35229

Abstract

Medulloblastoma is the second most common and most malignant brain tumor in children. But in adults medulloblastomas occur rarely. The patients with medulloblastoma are stratified two groups before treatment: avarage risk and high risk. Surgical resection followed by craniospinal irradiation (CSI) has been the mainstay of medulloblastoma therapy. In recent years, chemotherapy has been introduced to reduce the total dose of radiation and increase the survival rate. The new radiotherapy techniques and chemotherapy agents increase compliance to treatment.

Keywords

Medulloblastoma Craniospinal Radiotherapy Radiotherapy

References

  • Yazigi-Rivard L, Masserot C, Lachenaud J, Diebold- Pressac I, Aprahamian A, Avran D, Doz F. [Childhood 2008;15:1794-804 Arch Pediatr
  • Brada M. Pathology and Genetics of Tumours of the Nervous System. Br J Cancer 2001;84:148
  • Heideman RL, Packer RJ, Albright LA, Freeman CR, Rorke LB. Tumors of the central nervous system. In: Pizzo PA and Poplack DG, editors.Principles and Practice of Pediatric Oncology, 3rd edition. Philadelphia,USA: Philip, Lippincott-Raven, 1997
  • Kun LE. Brain tumors in children. In: Perez CA and Brandy LW, editors. Principles and Practice of Radiation Oncology. 3rd Edition. Philadelphia,USA: Lippincott-Raven, 1997 HJ: 5. Bloom Medulloblastoma:
  • prospects Int J Radiat Oncol Biol Phys 1977;2:1031- 1033 Prognosis and
  • Dai CY, Nakamura JL, Haas-Kogan D. Central Nervous System. In: Hansen EK, Roach III M, editors. Handbook of evidence based radiation oncology. New York, NY: Springer; 2006:15-54
  • Kun LE, Tarbell NJ. Current Treatment and Contraversies in Childhood Brain Tumors. In: ASTRO Education session. Atlanta, GA; 2004
  • Polkinghorn WR, Tarbell NJ. Medulloblastoma: tumorigenesis, currentcinical paradigm, and efforts to improve risk stratification. Nat Clin Pract Oncol 2007;5:295-304
  • Rood BR, Macdonald TJ, Packer RJ. Current treatment of medulloblastoma: Recent advances and future challenges. Semin Oncol 2004;31:666-75
  • Vezina LG, Packer RJ. Infratentorial brain tumors of childhood. 1994;4:423-436 Clin North Am
  • Packer RJ, Goldwein J, Nicholson HS, et al. Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A Children’s Cancer Group Study. J Clin Oncol 1999;17:2127-36
  • Yao MS, Mehta MP, Boyett JM, et al. The effect of M-stage on patterns of failure in posterior fossa pri- mitive neuroectodermal tumors treated on CCG-921: a phase III study in a high-risk patient population. Int J Radiat Oncol Biol Phys 1997;38:469-76
  • Lamont JM, McManamy CS, Pearson AD, Clifford SC, Ellison DW. Combined histopathological and molecular medulloblastoma 2004;10:5482-93
  • stratification Clin Res patients. Cancer
  • Chintagumpala M, Berg S, Blaney SM. Treatment contraversies in medulloblastoma. Curr Opin Oncol 2001;13:154-9
  • Zeltzer PM, Boyett JM, Finlay JL, et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children’s Cancer Group 921 randomized phase III study. J Clin Oncol 1999;17:832-45
  • Kühl J, Müller HL, Berthold F, et al. Pre-radiation chemotherapy of children and young adults with ma- lignant brain tumors: results of German pilot trial HIT’88/89. Klin Paeditr 1998;17:832-45
  • Krischer JP, Ragap AH, Kun L, et al. Nitrogen mustard, vincristine, procarbazine and prednisone as adjuvan medulloblastoma. A Pediatric Oncology Group study. J Neurosurg 1991;74:905-9 in the treatment of
  • Bailey CC, Gnekow A, Wellek S, et al. Prospective randomised trial of chemotherapy given before radiotherapy International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II. Med Pediatr Oncol 1995;25:166-78
  • Evans AE, Jenkin RD, Sposto R, et al. The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. J Neurosurg 1990;72:572-82
  • Tait DM, Thornton-Jones H, Bloom HJ, Lemerle J, Morris medulloblastoma: the first multi-centre control trial of the International Society of Paediatric Oncology (SIOP I). Eur J Cancer 1990;26:464-9 for
  • Schell MJ, McHaney VA, Green AA, et al. Hearing loss in children and young adults receiving cisplatin with or without prior cranial irradiation. J Clin Oncol 1989;7:754-60
  • Ertaş G, Uçer AR, Altundag MB, Durmus S, Calikoglu T, Ozbagi K, Abanuz H, Altundag K, Demirkasimoglu neuroectodermal tumor in adults: prognostic factors and treatment results: a single-center experience from Turkey. Med Oncol 2008;25:69-72
  • Thomas PR, Deutsch M, Kepner JL, et al. Low-stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation. J Clin Oncol 2000;18:3004-11
  • St. Clair WH, Adams JA, Bues M, et al. Advantage of protons compared to conventional X-Ray or IMRT in the treatment of a pediatric patient with medulloblastoma. Int J Radiat Oncol Biol Phys 2004;38:727-34
  • Jain N, Krull KR, Brouwers P, Chintagumpala MM, Woo SY. Neuropsychological outcome following intensity-modulated radiation therapy for pediatric medulloblastoma. Pediatr Blood Cancer 2008;51:275- 9
  • Lin R, Hug EB, Schaefer BS, et al. Conformal proton radiation therapy of the posterior fossa: A study comparing protons with three-dimensional planned photons in limiting dose to auditory structures. Int J Radiat Oncol Biol Phys 2000;48:1219-26
  • Parker W, Filion E, Roberge D, Freeman CR. Intensity-modulated radiotherapy for craniospinal irradiation: target volume considerations, dose constraints, and competing risks Int J Radiat Oncol Biol Phys. 2007;69:251-7
  • Parker WA, Freeman CR. A simple technique for craniospinal radiotherapy in the supine position. Radiother Oncol 2006;78:217-22
  • Liu M, Carrie C, Parker W, Freeman CR. Comprasion of manual and computer-generated customized blocks for whole brain fields used in the treatment of medulloblastoma. Med Pediatr Oncol 2002;38:55-7
  • Carrie C, Hoffstetter S, Gomez F, et al. Impact of targeting medulloblastoma:Study of the French Society of Pediatric Oncology (SFOP).Int J Radiat Oncol Biol Phys 1999;45:435-9 on outcome in
  • Hall EJ, Wuu CS. Radiation-induced second cancers:The impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys 2003;56:83-8
  • International Commission on Radiation Units and Measurements. Prescribing, recording, and reporting photon beam therapy. Bethesda, MD:ICRU;1999
  • Survivors of Childhood Cancer: Assessment and Ma- nagement. St. Louis, Mo: Mosby; 1994.
  • Brandes AA, Franceschi E, Tosoni A. Adult neuroectodermal (medulloblastoma) and of supratentorial sites (stPNET). Crit Rev Oncol Hematol 2009;71:165-79

Medulloblastoma ve Güncel Tedavi Yaklaşımları

Year 2013, Volume: 46 Issue: 1, 32 - 38, 01.04.2013

Özlem Derinalp Or Yıldız Yükselen Güney Ayşen Dizman Gonca Altınışık İnan Gülhan Güler Avcı Muzaffer Bedri Altundag

https://doi.org/10.5505/aot.2013.35229

Abstract

Medulloblastom çocukluk çağının ikinci en sık görülen ve en malign beyin tümörüdür. Yetişkinlerde ise oldukça nadir rastlanır. Medulloblastom tanılı hastalar tedavi öncesi standart risk ve yüksek riskli olmak üzere iki gruba ayrılır. Cerrahi rezeksiyonu takiben kraniospinal radyoterapi (KSRT) tedavinin temelini oluşturur. Günümüzde tedaviye kemoterapinin eklenmesi sağkalımın artmasına katkıda bulunmuştur. Ayrıca kemoterapinin eklenmesi ile total radyoterapi dozu da düşürülmüştür. Tedavide yeni kemoterapik ajanların geliştirilmesi ve yeni radyoterapi teknikleri hastaların uyumunu arttırmıştır.

Keywords

Medulloblastom Kraniospinal Işınlama Radyoterapi

References

  • Yazigi-Rivard L, Masserot C, Lachenaud J, Diebold- Pressac I, Aprahamian A, Avran D, Doz F. [Childhood 2008;15:1794-804 Arch Pediatr
  • Brada M. Pathology and Genetics of Tumours of the Nervous System. Br J Cancer 2001;84:148
  • Heideman RL, Packer RJ, Albright LA, Freeman CR, Rorke LB. Tumors of the central nervous system. In: Pizzo PA and Poplack DG, editors.Principles and Practice of Pediatric Oncology, 3rd edition. Philadelphia,USA: Philip, Lippincott-Raven, 1997
  • Kun LE. Brain tumors in children. In: Perez CA and Brandy LW, editors. Principles and Practice of Radiation Oncology. 3rd Edition. Philadelphia,USA: Lippincott-Raven, 1997 HJ: 5. Bloom Medulloblastoma:
  • prospects Int J Radiat Oncol Biol Phys 1977;2:1031- 1033 Prognosis and
  • Dai CY, Nakamura JL, Haas-Kogan D. Central Nervous System. In: Hansen EK, Roach III M, editors. Handbook of evidence based radiation oncology. New York, NY: Springer; 2006:15-54
  • Kun LE, Tarbell NJ. Current Treatment and Contraversies in Childhood Brain Tumors. In: ASTRO Education session. Atlanta, GA; 2004
  • Polkinghorn WR, Tarbell NJ. Medulloblastoma: tumorigenesis, currentcinical paradigm, and efforts to improve risk stratification. Nat Clin Pract Oncol 2007;5:295-304
  • Rood BR, Macdonald TJ, Packer RJ. Current treatment of medulloblastoma: Recent advances and future challenges. Semin Oncol 2004;31:666-75
  • Vezina LG, Packer RJ. Infratentorial brain tumors of childhood. 1994;4:423-436 Clin North Am
  • Packer RJ, Goldwein J, Nicholson HS, et al. Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A Children’s Cancer Group Study. J Clin Oncol 1999;17:2127-36
  • Yao MS, Mehta MP, Boyett JM, et al. The effect of M-stage on patterns of failure in posterior fossa pri- mitive neuroectodermal tumors treated on CCG-921: a phase III study in a high-risk patient population. Int J Radiat Oncol Biol Phys 1997;38:469-76
  • Lamont JM, McManamy CS, Pearson AD, Clifford SC, Ellison DW. Combined histopathological and molecular medulloblastoma 2004;10:5482-93
  • stratification Clin Res patients. Cancer
  • Chintagumpala M, Berg S, Blaney SM. Treatment contraversies in medulloblastoma. Curr Opin Oncol 2001;13:154-9
  • Zeltzer PM, Boyett JM, Finlay JL, et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children’s Cancer Group 921 randomized phase III study. J Clin Oncol 1999;17:832-45
  • Kühl J, Müller HL, Berthold F, et al. Pre-radiation chemotherapy of children and young adults with ma- lignant brain tumors: results of German pilot trial HIT’88/89. Klin Paeditr 1998;17:832-45
  • Krischer JP, Ragap AH, Kun L, et al. Nitrogen mustard, vincristine, procarbazine and prednisone as adjuvan medulloblastoma. A Pediatric Oncology Group study. J Neurosurg 1991;74:905-9 in the treatment of
  • Bailey CC, Gnekow A, Wellek S, et al. Prospective randomised trial of chemotherapy given before radiotherapy International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II. Med Pediatr Oncol 1995;25:166-78
  • Evans AE, Jenkin RD, Sposto R, et al. The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. J Neurosurg 1990;72:572-82
  • Tait DM, Thornton-Jones H, Bloom HJ, Lemerle J, Morris medulloblastoma: the first multi-centre control trial of the International Society of Paediatric Oncology (SIOP I). Eur J Cancer 1990;26:464-9 for
  • Schell MJ, McHaney VA, Green AA, et al. Hearing loss in children and young adults receiving cisplatin with or without prior cranial irradiation. J Clin Oncol 1989;7:754-60
  • Ertaş G, Uçer AR, Altundag MB, Durmus S, Calikoglu T, Ozbagi K, Abanuz H, Altundag K, Demirkasimoglu neuroectodermal tumor in adults: prognostic factors and treatment results: a single-center experience from Turkey. Med Oncol 2008;25:69-72
  • Thomas PR, Deutsch M, Kepner JL, et al. Low-stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation. J Clin Oncol 2000;18:3004-11
  • St. Clair WH, Adams JA, Bues M, et al. Advantage of protons compared to conventional X-Ray or IMRT in the treatment of a pediatric patient with medulloblastoma. Int J Radiat Oncol Biol Phys 2004;38:727-34
  • Jain N, Krull KR, Brouwers P, Chintagumpala MM, Woo SY. Neuropsychological outcome following intensity-modulated radiation therapy for pediatric medulloblastoma. Pediatr Blood Cancer 2008;51:275- 9
  • Lin R, Hug EB, Schaefer BS, et al. Conformal proton radiation therapy of the posterior fossa: A study comparing protons with three-dimensional planned photons in limiting dose to auditory structures. Int J Radiat Oncol Biol Phys 2000;48:1219-26
  • Parker W, Filion E, Roberge D, Freeman CR. Intensity-modulated radiotherapy for craniospinal irradiation: target volume considerations, dose constraints, and competing risks Int J Radiat Oncol Biol Phys. 2007;69:251-7
  • Parker WA, Freeman CR. A simple technique for craniospinal radiotherapy in the supine position. Radiother Oncol 2006;78:217-22
  • Liu M, Carrie C, Parker W, Freeman CR. Comprasion of manual and computer-generated customized blocks for whole brain fields used in the treatment of medulloblastoma. Med Pediatr Oncol 2002;38:55-7
  • Carrie C, Hoffstetter S, Gomez F, et al. Impact of targeting medulloblastoma:Study of the French Society of Pediatric Oncology (SFOP).Int J Radiat Oncol Biol Phys 1999;45:435-9 on outcome in
  • Hall EJ, Wuu CS. Radiation-induced second cancers:The impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys 2003;56:83-8
  • International Commission on Radiation Units and Measurements. Prescribing, recording, and reporting photon beam therapy. Bethesda, MD:ICRU;1999
  • Survivors of Childhood Cancer: Assessment and Ma- nagement. St. Louis, Mo: Mosby; 1994.
  • Brandes AA, Franceschi E, Tosoni A. Adult neuroectodermal (medulloblastoma) and of supratentorial sites (stPNET). Crit Rev Oncol Hematol 2009;71:165-79
There are 35 citations in total.

Details

Primary Language Turkish
Journal Section Articles
Authors

Özlem Derinalp Or This is me

Yıldız Yükselen Güney This is me

Ayşen Dizman This is me

Gonca Altınışık İnan This is me

Gülhan Güler Avcı This is me

Muzaffer Bedri Altundag This is me

Publication Date April 1, 2013
Published in Issue Year 2013 Volume: 46 Issue: 1

Cite

APA Or, Ö. D. ., Güney, Y. Y. ., Dizman, A. ., İnan, G. A. ., et al. (2013). Medulloblastoma ve Güncel Tedavi Yaklaşımları. Acta Oncologica Turcica, 46(1), 32-38. https://doi.org/10.5505/aot.2013.35229
AMA Or ÖD, Güney YY, Dizman A, İnan GA, Avcı GG, Altundag MB. Medulloblastoma ve Güncel Tedavi Yaklaşımları. Acta Oncologica Turcica. April 2013;46(1):32-38. doi:10.5505/aot.2013.35229
Chicago Or, Özlem Derinalp, Yıldız Yükselen Güney, Ayşen Dizman, Gonca Altınışık İnan, Gülhan Güler Avcı, and Muzaffer Bedri Altundag. “Medulloblastoma Ve Güncel Tedavi Yaklaşımları”. Acta Oncologica Turcica 46, no. 1 (April 2013): 32-38. https://doi.org/10.5505/aot.2013.35229.
EndNote Or ÖD, Güney YY, Dizman A, İnan GA, Avcı GG, Altundag MB (April 1, 2013) Medulloblastoma ve Güncel Tedavi Yaklaşımları. Acta Oncologica Turcica 46 1 32–38.
IEEE Ö. D. . Or, Y. Y. . Güney, A. . Dizman, G. A. . İnan, G. G. . Avcı, and M. B. . Altundag, “Medulloblastoma ve Güncel Tedavi Yaklaşımları”, Acta Oncologica Turcica, vol. 46, no. 1, pp. 32–38, 2013, doi: 10.5505/aot.2013.35229.
ISNAD Or, Özlem Derinalp et al. “Medulloblastoma Ve Güncel Tedavi Yaklaşımları”. Acta Oncologica Turcica 46/1 (April 2013), 32-38. https://doi.org/10.5505/aot.2013.35229.
JAMA Or ÖD, Güney YY, Dizman A, İnan GA, Avcı GG, Altundag MB. Medulloblastoma ve Güncel Tedavi Yaklaşımları. Acta Oncologica Turcica. 2013;46:32–38.
MLA Or, Özlem Derinalp et al. “Medulloblastoma Ve Güncel Tedavi Yaklaşımları”. Acta Oncologica Turcica, vol. 46, no. 1, 2013, pp. 32-38, doi:10.5505/aot.2013.35229.
Vancouver Or ÖD, Güney YY, Dizman A, İnan GA, Avcı GG, Altundag MB. Medulloblastoma ve Güncel Tedavi Yaklaşımları. Acta Oncologica Turcica. 2013;46(1):32-8.